Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of ZHB206 injection in acute ischemic stroke
CTR20242215Phase 2Completed
- Sponsor
- Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
- Start
- Jun 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ZHB206 in ischemic stroke, sponsored by Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute. Started Jun 2024; status: completed.
02
Drugs
ZHB206
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20242215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242215.